{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:33:16Z","timestamp":1777606396312,"version":"3.51.4"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 P30CA008748"],"award-info":[{"award-number":["P30 P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182665","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T14:04:24Z","timestamp":1501769064000},"page":"e0182665","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":54,"title":["Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-8427","authenticated-orcid":true,"given":"Kathryn C.","family":"Arbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith E.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre L.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Rekhtman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyson","family":"Karakunnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"WD Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"C Bernard","year":"2016","journal-title":"Autoimmun Rev"},{"key":"ref3","first-page":"1810","article-title":"Clinical Characteristics and Outcomes for Patients with Thymic Carcinoma: Evaluation of Masaoka Staging","volume":"9","author":"AM Litvak","year":"2014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma","volume":"29","author":"GL Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"PJ Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/JTO.0b013e318292c41e","article-title":"A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel\/Cisplatin for Masaoka Stage III\/IV thymic Epithelial Tumors","volume":"8","author":"S Park","year":"2013","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"A Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors","volume":"29","author":"G Giaccone","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"G Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.athoracsur.2003.07.042","article-title":"WHO histologic classification is a prognostic indicator in thymoma","volume":"77","author":"K Kondo","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"ref11","article-title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the \u201cBlueprint PD-L1 IHC Assay Comparison Project.\u201d","author":"FR Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"ref12","article-title":"Safety and Efficacy of Durvalumab (MEDI4736), an Anti\u2013Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer","author":"C Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","article-title":"Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"11","author":"MC Rebelatto","year":"2016","journal-title":"Diagn Pathol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"H Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"J Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"RJ Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"V Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"WA Cooper","year":"2015","journal-title":"Lung Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"M Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1200\/JCO.2017.35.15_suppl.8573","article-title":"Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study","volume":"35","author":"G Giaccone","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying Cancers Based on T-cell Infiltration and PD-L1","volume":"75","author":"MWL Teng","year":"2015","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"SF Ngiow","year":"2011","journal-title":"Cancer Res"},{"key":"ref23","article-title":"Isolation of T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes based on CD137 expression","author":"MR Parkhurst","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse High Intensity PD\u2013L1 Staining in Thymic Epithelial Tumors","volume":"10","author":"SK Padda","year":"2015","journal-title":"J Thorac Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Y Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma","volume":"22","author":"S Yokoyama","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref27","article-title":"A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non\u2013Small Cell Lung Cancer","author":"DL Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"M Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"ref29","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","author":"A Weissferdt","year":"2017","journal-title":"Mod Pathol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T20:38:50Z","timestamp":1569962330000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182665"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182665","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}